Vor Biopharma Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-696.0M | $-116.9M | $-117.9M | $-92.1M | $-68.9M | $-43.3M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $2.9M | $3.5M | $3.5M | $2.5M | $1.4M | $605.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $18.9M | $9.8M | $13.4M | $10.7M | $4.3M | $1.3M |
| Net Cash from Operating Activities | $-142.7M | $-99.7M | $-100.3M | $-85.1M | $-69.1M | $-36.3M |
| Investing Activities | ||||||
| Capital Expenditures | $941.0K | $229.0K | $1.1M | $8.5M | $3.9M | $4.2M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-48.8M | $96.9M | $71.0M | $-94.1M | $-91.7M | $-4.2M |
| Financing Activities | ||||||
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $503.8M | $53.4M | $2.9M | $117.1M | $232.9M | $82.5M |
| Net Change in Cash | $312.3M | $50.6M | $-26.3M | $-62.1M | $72.1M | $42.1M |
| Free Cash Flow | $-143.7M | $-99.9M | $-101.4M | $-93.6M | $-73.0M | $-40.5M |